Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China

(2020) David S. Hui et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle

(2020) Hongzhou Lu et al.   JOURNAL OF MEDICAL VIROLOGY

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

(2020) Nanshan Chen et al.   LANCET

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

(2020) Chaolin Huang et al.   LANCET

A pneumonia outbreak associated with a new coronavirus of probable bat origin

(2020) Peng Zhou et al.   NATURE

Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2

(2020) Renhong Yan et al.   SCIENCE

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

(2020) Xiaolong Tian et al.   Emerging Microbes & Infections

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

(2020) Chenguang Shen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

COVID-19 and Racial/Ethnic Disparities

(2020) Monica Webb Hooper et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The convalescent sera option for containing COVID-19

(2020) Arturo Casadevall et al.   JOURNAL OF CLINICAL INVESTIGATION

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

(2020) Jun Lan et al.   NATURE

Convalescent serum lines up as first-choice treatment for coronavirus

(2020) Cormac Sheridan   NATURE BIOTECHNOLOGY

Cell entry mechanisms of SARS-CoV-2

(2020) Jian Shang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

(2020) Kai Duan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Development of an inactivated vaccine candidate for SARS-CoV-2

(2020) Qiang Gao et al.   SCIENCE

SARS-CoV-2 (COVID-19) by the numbers

(2020) Yinon M Bar-On et al.   eLife

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

(2020) Bette Korber et al.   CELL

Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients

(2020) Xiaoli Wang et al.   CLINICAL INFECTIOUS DISEASES

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes

(2020) Shengli Xia et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Clinical characteristics of 225 patients with COVID-19 in a tertiary Hospital near Wuhan, China

(2020) Ruoqing Li et al.   JOURNAL OF CLINICAL VIROLOGY

Multisystem Inflammatory Syndrome in Children Associated with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Multi-institutional Study from New York City

(2020) Shubhi Kaushik et al.   JOURNAL OF PEDIATRICS

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

(2020) Feng-Cai Zhu et al.   LANCET

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

(2020) Pedro M Folegatti et al.   LANCET

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

(2020) Quan-Xin Long et al.   NATURE MEDICINE

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

(2020) Lisa A. Jackson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

(2020) Thomas F. Rogers et al.   SCIENCE

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

(2020) Denis Y Logunov et al.   LANCET

SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates

(2020) Gregory A Poland et al.   LANCET

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

(2020) Shengli Xia et al.   LANCET INFECTIOUS DISEASES

SARS-CoV-2 vaccines in development

(2020) Florian Krammer   NATURE

Evolution of the COVID-19 vaccine development landscape

(2020) Tung Thanh Le et al.   NATURE REVIEWS DRUG DISCOVERY

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

(2020) Edward E. Walsh et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

(2020) Evan J. Anderson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

(2020) Cheryl Keech et al.   NEW ENGLAND JOURNAL OF MEDICINE

ECMO support in SARS-CoV2 multisystem inflammatory syndrome in children in a child

(2020) Shubhi Kaushik et al.   PERFUSION-UK

Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China

(2020) Fan Wu et al.   JAMA Internal Medicine

Cerebral Venous Sinus Thrombosis in COVID-19 Infection: A Case Series and Review of The Literature

(2020) Katarina Dakay et al.   Journal of Stroke & Cerebrovascular Diseases

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

(2020) Yanjun Zhang et al.   LANCET INFECTIOUS DISEASES

Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer

(2019) Lukai Zhai et al.   ANTIVIRAL RESEARCH

PEGylated liposomes: immunological responses

(2019) Marwa Mohamed et al.   SCIENCE AND TECHNOLOGY OF ADVANCED MATERIALS

Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2

(2015) Ebenezer Tumban et al.   VACCINE

Long Term Storage of Dry versus Frozen RNA for Next Generation Molecular Studies

(2014) Eric Seelenfreund et al.   PLoS One

Pre-existing immunity against Ad vectors

(2014) Hugues Fausther-Bovendo et al.   Human Vaccines & Immunotherapeutics

Correction: Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus

(2012) Chien-Te Tseng et al.   PLoS One

A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity

(2012) Matthew D. J. Dicks et al.   PLoS One

International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations

(2011) Dan H. Barouch et al.   VACCINE

The prevalence of antibodies to adenovirus serotype 5 in an adult Indian population and implications for adenovirus vector vaccines

(2010) Rajendra Pilankatta et al.   JOURNAL OF MEDICAL VIROLOGY